With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is Rp 782.555,88, with a 24-hour trading volume of Rp 10,86T. The asset's market cap is Rp 3,46P, after moving 0.29% in the last day.
Tokenized Novo Nordisk A/S is trading at Rp 797.011,99, with a tokenized market cap of Rp 589,62B and a 24-hour trading volume of Rp 23,77B. The tokenized asset has moved 3.39% in the past 24 hours.